Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
holding | HSCS | Common Stock | 7.88K | Jun 14, 2022 | Direct |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
holding | HSCS | Director Stock Option (Right to Buy) | Jun 14, 2022 | Common Stock | 3.03K | $1.29 | Direct | F1 | ||||||
holding | HSCS | Director Stock Option (Right to Buy) | Jun 14, 2022 | Common Stock | 1.89K | $3.47 | Direct | F2 | ||||||
holding | HSCS | Warrants | Jun 14, 2022 | Common Stock | 6.46K | $5.16 | Direct | |||||||
holding | HSCS | Director Stock Option (Right to Buy) | Jun 14, 2022 | Common Stock | 1.89K | $3.47 | Direct | F3 |
Id | Content |
---|---|
F1 | The option becomes fully-vested and may be exercised at any time at Holder's election upon the achievement of performance-based criteria related to approval by the U.S. Food and Drug Administration of certain of the Company's products. As of the date of this filing, the performance-based criteria have not been satisfied. |
F2 | The option becomes fully-vested and may be exercised at any time at Holder's election upon the achievement of performance-based criteria related to approval by the U.S. Food and Drug Administration of certain of the Company's products. As of the date of this filing, the performance-based criteria have not been satisfied. |
F3 | The entire option has become fully-vested and may be exercised at any time at the Holder's election. |